Cargando…

Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis

PURPOSE OF REVIEW: Dual antiplatelet therapy (DAPT)—aspirin in conjunction with a P2Y(12) inhibitor—is the cornerstone of managing patients with acute coronary syndromes post-revascularization, but the clinical response is highly variable, with potentially devastating consequences. Herein, we review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shpigelman, Jonathan, Proshkina, Anastasia, Daly, Michael J., Cox, Dermot
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Cardiovascular Genomics (KG Aragam, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307718/ https://www.ncbi.nlm.nih.gov/pubmed/37261665 http://dx.doi.org/10.1007/s11886-023-01892-9

Ejemplares similares

Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk
por: Haring, Bernhard, et al.
Publicado: (2022)

Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy
por: Karanasos, Antonios, et al.
Publicado: (2014)

Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients
por: Dong, Liang, et al.
Publicado: (2022)

Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy
por: de Breet, C. P. D. M., et al.
Publicado: (2021)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
por: Tsigkas, Grigorios, et al.
Publicado: (2023)

Incorporation of Laboratory Test Biomarkers Into Dual Antiplatelet Therapy Score Improves Prediction of Ischemic and Bleeding Events in Post-percutaneous Coronary Intervention Patients
por: Sun, Chengming, et al.
Publicado: (2022)

Effect of dual antiplatelet therapy prolongation in acute coronary syndrome patients with both high ischemic and bleeding risk: insight from the OPT-CAD study
por: Na, Kun, et al.
Publicado: (2023)

Antiplatelet Therapy for Every Diabetic Person?
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon
por: Zhang, Yuxuan, et al.
Publicado: (2021)

Dual Antiplatelet Therapy vs. Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis
por: Zhang, Yipeng, et al.
Publicado: (2021)

Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
por: Park, Hanbit, et al.
Publicado: (2021)

Inflammatory Rheumatic Disorders and Bone
por: Bultink, Irene E. M., et al.
Publicado: (2012)

Dual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding
por: Carlin, Neal, et al.
Publicado: (2017)

Dual Loading Antiplatelet Therapy in Patients With Acute Coronary Syndrome and High Bleeding Risk Undergoing Percutaneous Coronary Intervention: Findings From the Improving Care for Cardiovascular Disease in China Project
por: Yan, Yan, et al.
Publicado: (2022)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?
por: Rogula, Sylwester P., et al.
Publicado: (2020)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
por: Yeh, Jong-Shiuan, et al.
Publicado: (2023)

Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating ‘target trials’ (the ADAPTT Study)
por: Pufulete, Maria, et al.
Publicado: (2019)

The Clinical Impact of Proton Pump Inhibitors When Co-Administered With Dual Antiplatelet Therapy in Patients Having Acute Myocardial Infarction With Low Risk of Gastrointestinal Bleeding: Insights From the China Acute Myocardial Infarction Registry
por: Shi, Wence, et al.
Publicado: (2021)

Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation
por: Staudacher, Dawid L., et al.
Publicado: (2016)

Clinical Evaluation of Role of Dual Antiplatelet Therapy on Bleeding after Dental Extraction
por: Babaji, Prashant, et al.
Publicado: (2018)

Risk of bleeding in patients with continued dual antiplatelet therapy during orthopedic surgery
por: Hu, San-Bao, et al.
Publicado: (2019)

Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease
por: Tung, Ying-Chang, et al.
Publicado: (2020)

Clinical Impact of Single and Dual Antiplatelet Therapy Beyond 12 Months on Ischemic Risk in Patients With Acute Myocardial Infarction
por: Roh, Ji Woong, et al.
Publicado: (2021)

Prolonged dual antiplatelet therapy for Chinese ACS patients undergoing emergency PCI with drug-eluting stents: Benefits and risks
por: Zhang, Yong, et al.
Publicado: (2023)

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
por: Cheng, Yujing, et al.
Publicado: (2023)

Mitochondrial proteases strike the right balance
por: Short, Ben
Publicado: (2009)

The Role of Antiplatelet Therapy in Patients With MINOCA
por: Ortega-Paz, Luis, et al.
Publicado: (2022)

Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study
por: Green, Anders, et al.
Publicado: (2016)

Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
por: Lee, Kwan Yong, et al.
Publicado: (2022)

Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases
por: Valke, Lars L. F. G., et al.
Publicado: (2022)

BF066, a Novel Dual Target Antiplatelet Agent without Significant Bleeding
por: Pan, ChangE, et al.
Publicado: (2012)

Patient perspectives of nuisance bleeding and adherence to dual antiplatelet therapy: a qualitative study
por: Pithara, Christalla, et al.
Publicado: (2020)

Thrombosis and Major Bleeding Risk After Primary PCI Among Patients With Multivessel Coronary Artery Disease
por: Zhao, Xiaoxiao, et al.
Publicado: (2022)

Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial
por: Hernandez-Suarez, Dagmar F, et al.
Publicado: (2020)

Prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with diabetes mellitus: A nationwide retrospective cohort study
por: Lee, Seung-Jun, et al.
Publicado: (2022)

Striking the Right Balance Determines TB or Not TB
por: BoseDasgupta, Somdeb, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p4d9rbr8eeom4rjqrlr9r02j6q